Shaohong Luo
Overview
Explore the profile of Shaohong Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Huang Y, Huang X, Huang X, Lin S, Luo S, Gu D, et al.
Hum Reprod
. 2023 Apr;
38(6):1099-1110.
PMID: 37075316
Study Question: Is it economically worthwhile to use GnRH agonist (GnRHa) to prevent menopausal symptoms (MS) and protect fertility in premenopausal women with breast cancer (BC) during chemotherapy from the...
12.
Lin S, Lin D, Li Y, Zhong L, Zhou W, Wu Y, et al.
Epidemiol Health
. 2023 Mar;
45:e2023038.
PMID: 36996867
Objectives: The aim of this study was to evaluate the disease burden of prostate cancer (PC) and assess key influencing factors associated with the disease expenditures of PC in the...
13.
Huang X, Huang X, Lin S, Luo S, Dong L, Lin D, et al.
BMJ Open
. 2023 Mar;
13(3):e068943.
PMID: 36972963
Objective: Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone, once every 3 weeks (R-CHOP21) is commonly used in non-Hodgkin's lymphoma (NHL), but accompanied by pneumonia (PCP) as a fatal treatment complication....
14.
Lin S, Huang Y, Dong L, Li M, Wang Y, Gu D, et al.
Front Pharmacol
. 2023 Mar;
14:1114304.
PMID: 36909180
Life expectancy for patients with malignant tumors has been significantly improved since the presence of the programmed cell death protein-1/programmed cell death protein ligand-1 (PD-1/PD-L1) inhibitors in 2014, but they...
15.
Seitak A, Shanti A, Al Adem K, Farid N, Luo S, Iskandarov J, et al.
J Biomed Mater Res A
. 2022 Nov;
111(4):514-526.
PMID: 36371793
MXenes belong to a new class of two dimensional (2D) functional nanomaterials, mainly encompassing transition-metal carbides, nitrides and carbonitrides, with unique physical, chemical, electronic and mechanical properties for various emerging...
16.
Lin D, Luo S, Lin S, Zhong L, Zhou W, Gu D, et al.
Clin Genitourin Cancer
. 2022 Nov;
21(1):8-15.
PMID: 36328903
Background: Recently, a clinical trial (NCT02603432) showed that avelumab maintenance treatment, post first-line chemotherapy, can significantly prolong the overall survival of patients with advanced urothelial carcinoma (UC), however, the treatment...
17.
Lin S, Li Y, Gu D, Luo S, Huang X, Dong L, et al.
Front Oncol
. 2022 May;
12:857452.
PMID: 35530317
Objective: Recently, the significant improvement of atezolizumab and pembrolizumab over chemotherapy for treatment-naïve stage IV non-small cell lung cancer (NSCLC) has been demonstrated, but the cost-effectiveness of these regimens remains...
18.
Boularaoui S, Shanti A, Lanotte M, Luo S, Bawazir S, Lee S, et al.
ACS Biomater Sci Eng
. 2021 Nov;
7(12):5810-5822.
PMID: 34802227
There is a growing need to develop novel well-characterized biological inks (bioinks) that are customizable for three-dimensional (3D) bioprinting of specific tissue types. Gelatin methacryloyl (GelMA) is one such candidate...
19.
Luo S, Weng X, Lin S, Huang X, Huang L, Zhou W, et al.
Int J Clin Pharm
. 2021 Oct;
44(1):192-200.
PMID: 34633624
Background Few regimens for non-small cell lung cancer (NSCLC) with leptomeningeal metastases (LM) patients exist up to date, most with low efficacy. A retrospective analysis showed that osimertinib significantly improved...
20.
Li Y, Lin S, Zhong L, Luo S, Huang X, Huang X, et al.
Pharmacogenomics
. 2021 Sep;
22(13):809-819.
PMID: 34517749
To compare the cost-effectiveness of olaparib versus control treatment in metastatic castration-resistant prostate cancer patients with at least one gene mutation in , or from the US payer perspective. A...